Withdrawal from Chronic Phencyclidine Treatment Induces Long-Lasting Depression in Brain Reward Function
- 17 September 2002
- journal article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 28 (6) , 1106-1116
- https://doi.org/10.1038/sj.npp.1300124
Abstract
Phencyclidine (PCP) is a drug of abuse that has rewarding and dysphoric effects in humans. The complex actions of PCP, and PCP withdrawal in particular, on brain reward function remain unclear. The purpose of the present study was to characterize the effects of withdrawal from acute and chronic PCP treatment on brain reward function in rats. A brain stimulation reward procedure was used to evaluate the effects of acute PCP injection (0, 5, or 10 mg/kg) or chronic PCP treatment (0, 10, 15, or 20 mg/kg/day for 14 days delivered via subcutaneous osmotic minipumps) on brain reward function. Withdrawal from acute administration of 5 and 10 mg/kg PCP produced a decrease in brain reward function as indicated by a sustained elevation in brain reward thresholds. When administered chronically, 10, 15, or 20 mg/kg/day PCP induced a progressive dose-dependent potentiation of brain stimulation reward, while cessation of the treatment resulted in significant elevations in reward thresholds reflecting diminished reward. Specifically, withdrawal from 15 or 20 mg/kg/day PCP induced a depression in brain reward function that lasted for the entire month of observation. These results indicate that prolonged continuous administration of high PCP doses facilitates brain stimulation reward, while withdrawal from acute high PCP doses or chronic PCP treatment results in a protracted depression of brain reward function that may be analogous to the dysphoric and anhedonic symptoms observed in PCP dependence, depression, and schizophrenia.Keywords
This publication has 66 references indexed in Scilit:
- Continuous Phencyclidine Treatment Induces Schizophrenia-Like Hyperreactivity of Striatal Dopamine ReleaseNeuropsychopharmacology, 2001
- Interactions Between Monoamines, Glutamate, and GABA in Schizophrenia: New EvidenceAnnual Review of Pharmacology and Toxicology, 2001
- Role of Adenosine A2 Receptors in Brain Stimulation Reward under Baseline Conditions and during Cocaine Withdrawal in RatsJournal of Neuroscience, 1999
- Effects of abused drugs on thresholds and breaking points of intracranial self-stimulation in ratsEuropean Neuropsychopharmacology, 1999
- Microinjections of phencyclidine (PCP) and related drugs into nucleus accumbens shell potentiate medial forebrain bundle brain stimulation rewardPsychopharmacology, 1996
- Rewarding Actions of Phencyclidine and Related Drugs in Nucleus Accumbens Shell and Frontal CortexJournal of Neuroscience, 1996
- Differential Effects of MK-801 on Brain-Derived Neurotrophic Factor mRNA Levels in Different Regions of the Rat BrainExperimental Neurology, 1993
- Phencyclidine-induced potentiation of brain stimulation reward: acute effects are not altered by repeated administrationPsychopharmacology, 1993
- Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving ratsNeuroscience, 1989
- Place conditioning with morphine and phencyclidine: Dose dependent effectsLife Sciences, 1985